Incretin Atlas › Trials › LIGHTEN (HS-20094-301)
LIGHTEN (HS-20094-301)
HS-20094 · obesity
Design
- Molecule(s)
- HS-20094
- Population
- obesity
- Phase
- 3
- Participants
- 604
- Duration
- 48 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 mg | obesity china | 48 | 604 | −12.5 % vs −2.7 % Δ −9.8 pp | −11.8 % vs −2.5 % Δ −9.3 pp | — | — | — | — | — | — | — | congress |
| 10 mg | obesity china | 48 | 604 | −17.5 % vs −2.7 % Δ −14.8 pp | −17.0 % vs −2.5 % Δ −14.5 pp | — | — | — | — | — | — | — | congress |
| 15 mg | obesity china | 48 | 604 | −19.3 % vs −2.7 % Δ −16.6 pp | −18.7 % vs −2.5 % Δ −16.2 pp | — | — | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 5 mg: The release reports no discontinuations for treatment-related adverse events (pooled doses); discontinuation for any adverse event is not reported.
- 10 mg: The release reports no discontinuations for treatment-related adverse events (pooled doses); discontinuation for any adverse event is not reported.
- 15 mg: The release reports no discontinuations for treatment-related adverse events (pooled doses); discontinuation for any adverse event is not reported.
Verbatim quotes from the source (6)
- 5 mg · weight_tp · EQS release
Under the treatment-regimen estimand, mean body weight reductions were
- 5 mg · weight_eff · EQS release
under the efficacy estimand, mean body weight reductions at week 48
- 10 mg · weight_tp · EQS release
Under the treatment-regimen estimand, mean body weight reductions were
- 10 mg · weight_eff · EQS release
under the efficacy estimand, mean body weight reductions at week 48
- 15 mg · weight_tp · EQS release
Under the treatment-regimen estimand, mean body weight reductions were
- 15 mg · weight_eff · EQS release
under the efficacy estimand, mean body weight reductions at week 48
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66821.
- Hansoh Pharma. Olatorepatide phase III LIGHTEN data presented at EASD 2026 [EQS-News]. 2026 Oct 2. Available from: https://www.boersennews.de/nachrichten/meldungen/eqs/eqs-news-19-3-weight-loss-at-week-48-phase-data-of-olatorepatide-hansoh-s-dual-biased-glp-1-gip-agonist-presented-at-easd/5297659/
How to cite this page
Medical Adviser's Group. Incretin Atlas: LIGHTEN (HS-20094-301). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/lighten/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.